CARDINAL HEALTH INC (CAH)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CAH
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CAH | Former President and CEO, Eliem Therapeutics, Inc. | 57 | ["Former President and CEO, Eliem Therapeutics, Inc.", "extensive executive leadership experience across the biopharmaceutical, oncology, and specialty pharmaceutical sectors", "strategic oversight and operational leadership", "corporate governance", "commercial and manufacturing operations", "international markets", "finance", "human resources", "regulatory compliance"] | ["Audit Committee", "Compensation Committee"] | 2025 |
Biography sourced from the proxy statement filing.
Former President and CEO of Eliem Therapeutics, Inc. Independent Director Age: 57 Director since: 2024 Board Committees: Audit Risk Oversight Skills and Experience: Financial Expertise Healthcare Expertise Operations Experience Regulatory/Legal/Public Policy Experience International Experience DIRECTOR QUALIFICATIONS: Mr. Azelby brings extensive executive leadership experience across the biopharmaceutical, oncology, and specialty pharmaceutical sectors. His background includes strategic oversight and operational leadership in areas such as corporate governance, commercial and manufacturing operations, international markets, finance, human resources, and regulatory compliance. In addition to his executive leadership experience, Mr. Azelby contributes valuable insights to the Board gained through his service on the boards of several public biopharmaceutical companies. He currently serves on the Audit and Compensation Committees of ADC Therapeutics, the Audit and Nominating and Governance Committees of Autolus Therapeutics, and the Compensation Committee of Terns Pharmaceuticals. PROFESSIONAL EXPERIENCE: President and CEO of Eliem Therapeutics, Inc., a biotechnology company focused on neuronal excitability disorders (2020 2023) President and CEO of Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on prevention of chronic migraines (2018 2019) Executive Vice President and Chief Commercial Officer of Juno Therapeutics, Inc., a biopharmaceutical company (2015 2018) Held various senior roles at Amgen Inc., a multinational biopharmaceutical company (2000 2015) OTHER PUBLIC COMPANY DIRECTORSHIPS: Current: ADC Therapeutics SA (since 2023), Autolus Therapeutics plc (since 2024), Terns Pharmaceuticals, Inc. (since February 2025) Past: Chinook Therapeutics, Inc. (2023), Eliem Therapeutics, Inc. (2020 2023), Clovis Oncology, Inc. (2018 2022), Immunomedics, Inc. (2020)